Determinants of spironolactone binding specificity in the mineralocorticoid receptor.

Spironolactone is a mineralocorticoid receptor (MR) antagonist in clinical use. The compound has a very low affinity for the glucocorticoid receptor (GR). Determinants of binding specificity of spironolactone to the MR were investigated using chimeras created between the ligand-binding domains (LBDs) of the MR and the GR. These chimeras had previously been used to investigate aldosterone binding specificity to the MR. Spironolactone was able to compete strongly for [(3)H]-aldosterone and [(3)H]-dexamethasone binding to a chimera containing amino acids 804-874 of the MR, and weakly for [(3)H]-dexamethasone binding to a chimera containing amino acids 672-803 of the MR. Amino acids 804-874 were also critical for aldosterone binding specificity. Models of the MR LBD bound to aldosterone and spironolactone were created based on the crystal structure of the progesterone receptor LBD. The ligand-binding pocket of the MR LBD model consisted of 23 amino acids and was predominantly hydrophobic in nature. Analysis of this model in light of the experimental data suggested that spironolactone binding specificity is not governed by amino acids in the ligand-binding pocket.

[1]  S. Chu,et al.  Structural determinants of cortisol resistance in the guinea pig glucocorticoid receptor. , 1998, Endocrinology.

[2]  S. Doggrell,et al.  The spironolactone renaissance , 2001, Expert opinion on investigational drugs.

[3]  K. Koehler,et al.  Functional Probing of the Human Glucocorticoid Receptor Steroid-interacting Surface by Site-directed Mutagenesis , 2000, The Journal of Biological Chemistry.

[4]  S. Chu,et al.  Structural Determinants of Aldosterone Binding Selectivity in the Mineralocorticoid Receptor* , 1999, The Journal of Biological Chemistry.

[5]  D. Moras,et al.  A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones. , 2000, Molecular pharmacology.

[6]  N. Warriar,et al.  Reconstitution of the N-terminal Transcription Activation Function of Human Mineralocorticoid Receptor in a Defective Human Glucocorticoid Receptor* , 1998, The Journal of Biological Chemistry.

[7]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[8]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[9]  E. Baulieu,et al.  Aldosterone antagonists destabilize the mineralocorticosteroid receptor. , 1992, The Biochemical journal.

[10]  D. Pearce,et al.  Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. , 1996, Molecular endocrinology.

[11]  E. Baulieu,et al.  Spironolactone, an aldosterone antagonist, acts as an antiglucocorticosteroid on the mouse mammary tumor virus promoter. , 1992, Endocrinology.

[12]  P. Chambon,et al.  Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor. , 1996, Molecular endocrinology.

[13]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[14]  J. Harmon,et al.  Activation of the rat kidney mineralocorticoid receptor. , 1986, Endocrinology.

[15]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[16]  J. Funder,et al.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. , 1988, Science.

[17]  D. Moras,et al.  Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity. , 2000, Molecular endocrinology.

[18]  P. Fuller,et al.  Mineralocorticoid action , 2000, Steroids.

[19]  S. Kato,et al.  Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). , 2000, Molecular endocrinology.

[20]  D. Moras,et al.  Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.

[21]  G. Giannoukos,et al.  The Seven Amino Acids (547–553) of Rat Glucocorticoid Receptor Required for Steroid and Hsp90 Binding Contain a Functionally Independent LXXLL Motif That Is Critical for Steroid Binding* , 1999, The Journal of Biological Chemistry.

[22]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[23]  F. Holsboer,et al.  Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. , 1993, Molecular endocrinology.

[24]  F. Holsboer,et al.  Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. , 1993, European journal of pharmacology.

[25]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[26]  P. Sigler,et al.  Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. , 2000, Science.

[27]  T. Nemoto,et al.  Dual roles of 90-kDa heat shock protein in the function of the mineralocorticoid receptor. , 1993, Journal of biochemistry.

[28]  K. Geering,et al.  Mechanism of the antimineralocorticoid effects of spirolactones. , 1981, Kidney international.

[29]  J. Ménard,et al.  Antiandrogenic effect of spirolactones: mechanism of action. , 1975, Endocrinology.

[30]  A. Kralli,et al.  A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen , 2000, Molecular and Cellular Biology.

[31]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[32]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .